Galapagos hits brakes on lupus CAR-T, trims 100 jobs

2024-02-23

临床2期ASH会议财报临床1期

Belgian biotech Galapagos announced that it has discontinued development of its CD19 CAR-T project GLPG5101 for refractory systemic lupus erythematosus (rSLE), citing unspecified "strategic reasons." The company said in its 2023 financial results presentation that it also cut approximately 100 positions across the organisation to align with a "renewed focus on innovation."

Last August, Galapagos said it had filed an application in Europe to start Phase I development of its CD19 CAR-T candidate in patients with refractory SLE, but provided few other details since. That development has now been halted, although GLPG5101 remains in Phase II testing for relapsed/refractory non-Hodgkin's lymphoma (NHL), according to the company's website.

At the American Society of Hematology (ASH) conference late last year, the company reported that 6 of 7 evaluable NHL patients responded to treatment with GLPG5101 in the Phase II ATALANTA-1 study, including 4 who achieved complete responses. It said the therapy also had "an encouraging safety profile."